Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade

Catherine T. Flores; Tyler J. Wildes; Jeffrey A. Drake; Ginger L. Moore; Bayli DiVita Dean; Rebecca S. Abraham; Duane A. Mitchell

doi:10.1038/s41467-018-06182-5

Nature Communications (Oct 2018)

Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade

Catherine T. Flores,
Tyler J. Wildes,
Jeffrey A. Drake,
Ginger L. Moore,
Bayli DiVita Dean,
Rebecca S. Abraham,
Duane A. Mitchell

Affiliations

Catherine T. Flores: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida
Tyler J. Wildes: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida
Jeffrey A. Drake: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida
Ginger L. Moore: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida
Bayli DiVita Dean: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida
Rebecca S. Abraham: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida
Duane A. Mitchell: University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida

DOI: https://doi.org/10.1038/s41467-018-06182-5
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 14

Abstract

Read online

Brain tumors are difficult to treat using existing immunotherapeutic strategies. Here, the authors show that in brain tumors resistant to PD-1 blockade, HSCs expressing CCR2+ can reverse treatment resistance and sensitizes mice to immunotherapy.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal